Abstract:
Resorbable lactide polymer micro-membranes are disclosed. The micro-membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about O.300 mm. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be preshaped with relatively thick portions, and can be stored in sterile packages.
Abstract:
The present disclosure relates to compositions A composition comprising a polymerization product of an anionic polysaccharide, a diisocyanate, and a linker, wherein the linker comprises i) an ether group, an ester group, or a combination thereof and, ii) a chain extender comprising a hydroxyl group, a thiol group, an amine group, or a combination thereof. The disclosure further relates to medical devices comprising the aforementioned compositions, and to methods of using the compositions and devices. More particularly, the compositions, devices and methods described herein are useful for preventing protein adhesions in vivo, particularly the Vroman effect.
Abstract:
Described are mono- and bi-layer alginate post-surgical anti-adhesion barriers with tailored absorption profiles and non-migrating characteristics. Muco-adhesive properties of alginates in their solid state are used to localize the device, and lubricious properties of alginates in their liquid state are used to mitigate adhesion formation during wound healing. In addition, the design of the implant can be selected such that the crosslinking agent is released from the device under specific conditions and the absorbance profile modified. A medicinal agent may optionally be incorporated.
Abstract:
The present disclosure provides a medical assembly comprising a surgical barrier aspect comprising polylactic acid, and a hydrophilic mucoadhesive aspect, wherein the surgical barrier aspect is provided on a first side of the assembly and the mucoadhesive aspect is provided on a second side of the assembly. The disclosure also relates to a medical assembly comprising a surgical barrier aspect, a short term mucoadhesive aspect, an intermediate term protein polymerization adhesive aspect, and a long term tissue ingrowth implant localization aspect. The aforementioned medical assemblies may be provided as layered sheet structures. Also provided are methods for preparing a medical assembly.
Abstract:
A resorbable thin membrane is applied over a treatment site before a treatment is applied over the resorbable thin membrane to the site. In a particular implementation, a resorbable thin membrane is adhesively applied over a treatment site of tissue before a treatment is conducted onto the tissue whereby the treatment is performed through the resorbable thin membrane. The treatment can be an incision that is made through both the resorbable membrane and into or through the tissue.
Abstract:
Described are devices and methods for reinforcing a layer of living tissue, which when affixed to a tissue layer prior to surgical incision, reinforces the tissue to be incised, provides a fibro-conductive matrix to promote healing in a preferred plane, and provides for a subsequent closure and fluidic seal. A partially or entirely absorbable growth matrix is disclosed, comprising two adhesion-resistant layers enclosing a cellular conductive medium for promoting fibrosis in a preferred plane. The cellular conductive portion is partially or entirely sequestered from surrounding tissue. The device is constructed in a physiologic range of tensile strengths and elasticity suitable for closure of the pericardium, peritoneum, or other typically thin membranes enclosing organs in the body, whose function is to prevent adhesions between tissue surfaces normally in motion.
Abstract:
A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction.